The generic version of Nuvigil is possible to be released after 18 June, 2024. This is due to the expiry of the last patent, US7132570*PED, which protects the production of crystalline forms of the optical enantiomers of modafinil.
Nuvigil is used to treat excessive sleepiness caused by certain sleep disorders. It contains armodafinil, which helps to keep people awake.
Nuvigil holds a total of 4 drug patents, two of which have already expired. The remaining patents protect pharmaceutical formulations of modafinil and the production of crystalline forms of the optical enantiomers of modafinil. The last patent is expected to expire on 18 June, 2024. Below are the details of the patent: